Vanderbilt-Ingram website >
A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
Erlanger Health System and Vanderbilt University Medical Center, on behalf of Vanderbilt-Ingram Cancer Center (VICC), have entered into a professional service agreement designing a long-term collaboration in comprehensive cancer care, including VICC hematology-oncology services at Erlanger Oncology and Hematology and infusion locations.
Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.
Reagan Leverett, MD, MS, associate professor of Radiology and Radiological Sciences and medical director of Vanderbilt Breast Imaging Services, has been named chief of the Section of Breast Imaging, a position she previously held on an interim basis.
Vanderbilt-Ingram Cancer Center at Wilson County is slated to open Aug. 31 with a full array of highly specialized services, including diagnostic assessments, medical oncology and radiation oncology.
Accessibility Tools